5-3-04

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

Total Number of Pages in This Submission: 29

ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☑ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
- ☐ After Allowance communication to Technology Center (TC)
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☐ Other Enclosure(s) (please Identify below):

Remarks

Customer No. 38199
Express Mail No. EU531570788US

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	HOWSON AND HOWSON Cathy A. Kodroff
Signature	Cathy A. Kodroff
Date	April 30, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name			
Signature		Date	

AHPWA1DUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.	: 10/767,813	Confirmation No.: unassigned
Applicant	: Zhang et al.	
Filed	: January 29, 2004	
TC/A.U.	: unassigned	
Examiner	: unassigned	
Customer No.	: 38199	
Title	: CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of documents GH-GK, HB-HE, HK-IG, DM, and EO are enclosed herewith. This Information Disclosure Statement is being submitted more than three months from the filing date of this application but before the receipt of a first Office Action.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Express Mail No. EU531570788US

REMARKS

Listed below are previously filed, and co-pending, US Patent applications. These applications and the present application are commonly owned:

(1) U.S. Patent Application No. 09/552,633, filed April 19, 2002, now U.S. Patent No. 6,509,334, issued January 21, 2003 (item GC)

U.S. Patent Application No. 09/948,309, filed September 6, 2001, now U.S. Patent No. 6,566,358 issued May 20, 2003 (item GF)

U. S. Patent Application No. 10/386,799, filed March 12, 2003, now U.S. Patent No. 6,713,478, issued March 30, 2004 (item GK)

(2) U.S. Patent Application No. 09/552,632, filed April 19, 2000, now U.S. Patent No. 6,391,907, issued May 21, 2002 (item FB)

U.S. Patent Application No. 10/014,173, filed December 11, 2001, now U.S. Patent No. 6,608,068, issued August 18, 2003 (item GI)

U.S. Patent Application No. 10/456,892, filed June 6, 2003 (U.S. Patent Publication No. US-2003-0220388-A1, published November 27, 2003 (item HD))

(3) U.S Patent Application No. 09/552,352, filed April 19, 2000, now U.S. Patent No. 6,417,214, issued July 9, 2002 (item FE)

U.S. Patent Application No. 10/131,379, filed April 24, 2002 (U.S. Patent Publication No. US-2003-0008909-A1, published January 9, 2003 (item HH))

(4) U.S. Patent Application No. 09/552,033, filed April 19, 2000, now U.S. Patent No. 6,355,648, issued March 12, 2002 (item EG)

U.S. Patent Application No. 10/022,467, filed October 30, 2001, now U.S. Patent No. 6,521,657, issued February 18, 2003 (item GD)

U.S. Patent Application No. 10/117,156, filed April 5, 2002 (U.S. Patent Publication No. US-2002-0169198-A1, published November 14, 2002 (item HB))

U.S. Patent Application No. 10/253,380, filed September 24, 2002, now U.S. Patent No. 6,583,145, issued June 24, 2003 (item GG)

U.S. Patent Application No. 10/420,276, filed April 22, 2003 (U.S. Patent Publication No. US-2003-0225109-A1, published December 12, 2003 (item HE))

(5) U.S. Patent Application No. 09/552,354, filed April 19, 2000, now U.S. Patent No. 6,436,929, issued August 20, 2002 (item FG)

U.S. Patent Application No. 10/140,034, filed May 6, 2002 (U.S. Patent Publication No. U.S.-2003-0092711-A1, published May 15, 2003 (item HJ))

(6) U.S. Patent Application No. 09/552,546, filed April 19, 2000, now U.S. Patent No. 6,380,235, issued April 30, 2002 (item FA)

U.S. Patent Application No. 10/074,768, filed February 12, 2002 (U.S. Patent Publication No. US-2002-0115853-A1, published August 22, 2002 (HF))

(7) U.S. Patent Application No. 09/552,630, filed April 19, 2000, now U.S. Patent No. 6,339,098, issued January 15, 2002 (item EF)

(8) U.S. Patent Application No. 09/552,036, filed April 19, 2000, now U.S. Patent No. 6,306,851, issued October 23, 2001 (item EC)

U.S. Patent Application No. 09/906,875, filed July 17, 2001, now U.S. Patent No. 6,441,019, issued August 27, 2002 (item FH)

(9) U.S. Patent Application No. 09/552,356, filed April 19, 2000, now U.S. Patent No. 6,369,056, issued April 9, 2002 (item EJ)

U.S. Patent Application No. 10/050,287, filed January 16, 2002 (U.S. Patent Publication No. US-2002-0111355-A1, published August 15, 2002 (item IB))

(10) U.S. Patent Application No. 09/552,629, filed April 19, 2000, now U.S. Patent No. 6,358,948, issued March 19, 2002 (item EI)

U.S. Patent Application No. 10/023,063, filed December 17, 2001, now U.S. Patent No. 6,693,103, issued February 17, 2004 (item GJ)

(11) U. S. Patent Application No. 09/552,544, filed April 19, 2000, now U.S. Patent No. 6,407,101, issued June 18, 2002 (item FD)

U.S. Patent Application No. 10/043,513, filed January 9, 2002, now U.S. Patent No. 6,562,857, issued May 13, 2003 (item GH)

U.S. Patent Application No. 10/342,719, filed January 15, 2003 (U.S. Patent Publication No. US-2003-0158182-A1, published August 21, 2003 (item HC))

(12) U.S. Patent Application No. 09/552,357, filed April 19, 2000, now U.S. Patent No. 6,498,154, issued December 24, 2002 (item GA)

(13) U.S. Patent Application No. 09/552,037, filed April 19, 2000, now U.S. Patent No. 6,399,593, issued June 4, 2002 (item FC)

(14) U.S. Patent Application No. 09/552,350, filed April 19, 2000, now U.S. Patent No. 6,444,668, issued September 3, 2002 (item FJ)

U.S. Patent Application No. 10/141,792, filed May 9, 2002 (U.S. Patent Publication No. US-2003-0045511-A1, published March 6, 2003 (item HI))

(15) U.S. Patent Application No. 09/552,631, filed April 19, 2000, now U.S. Patent No. 6,329,416, issued December 11, 2001 (item EE)

U.S. Patent Application No. 09/977,790, filed October 15, 2001, now U.S. Patent No. 6,503,939, issued January 7, 2003 (item GB)

(16) U.S. Patent Application No. 09/552,355, filed April 19, 2000, now U.S. Patent No. 6,423,699, issued July 23, 2002 (item FF)

U.S. Patent Application No. 10/091,222, filed March 1, 2002 (U.S. Patent Publication No. US-2002-0151531-A1, published October 17, 2002 (item HG))

(17) U.S. Patent Application No. 09/552,545, filed April 19, 2000, now U.S. Patent No. 6,380,178, issued April 30, 2002 (item EK)

(18) U.S. Patent Application No. 09/552,358, filed April 19, 2000, now U.S. Patent No. 6,462,032, issued October 8, 2002 (item FK)

U.S. Patent Application No. 10/153,393 filed May 22, 2002, now U.S. Patent 6,544,970 issued April 8, 2003 (item GE)

(19) U.S. Patent Application No. 09/552,038, filed April 19, 2000, now U.S. Patent No. 6,319,912, issued November 20, 2001 (item ED)

(20) U.S. Patent Application No. 09/552,353 filed, April 19, 2000, now U.S. Patent No. 6,358,947, issued March 19, 2002 (item EH)

(21) U.S. Patent Application No. 10/601,442, filed June 23, 2003 (U.S. Patent Publication No. US-2004-0006122-A1, published January 8, 2004 (item IC))

(22) U.S. Patent Application No. 10/601,968, filed June 23, 2003 (U.S. Patent Publication No. US-2004-0014798-A1, published January 22, 2004 (item ID))

(23) U.S. Patent Application No. 10/601,438, filed June 23, 2003 (U.S. Patent Publication No. US-2004-0002535-A1, published January 1, 2004 (item IE))

(24) U.S. Patent Application No. 10/601,481, filed June 23, 2003 (U.S. Patent Publication No. US-2004-0006060-A1, published January 8, 2004 (item IF))

Applicants have also provided comments on the documents cited in this Information Disclosure Statement that were published in a language other than English. Specifically, Applicants have provided the following comments for the following documents.

(1) English translations of documents EQ and AL were not available. However, document BJ, U.S. Patent No. 5,414,088, issued May 9, 1995, corresponds to document EQ, International Patent Publication No. WO 91/04974, published April 18, 1991. Similarly, document BB, i.e. U.S. Patent No. 4,831,027, issued May 16, 1989, corresponds to document AL, German Patent No. 3,633,861, issued April 7, 1988. Further, document ES, is the corresponding Chemical Abstracts entry to document BB. Brief remarks on these documents follow:

(EQ) This document describes the preparation of bicyclobenzimidazoles and their use to inhibit erythrocyte and thrombocyte aggregation. Thus, these compounds are used to treat conditions such as arterial occlusive or ischaemic conditions, venous insufficiency or diabetes mellitus.

(AL) This document describes the preparation of imidazo-benzoxazinones, and pharmaceutical compositions containing them. These compounds are assertedly useful in the treatment of cardiovascular effects, particularly cardiotonic activity and antithrombotic activity, with little effect on blood pressure.

(2) English translations of documents CN, BM, BL, and DM were not available. Abstracts of these documents were obtained and were provided as documents BW, AV, AS, and DU respectively. Brief remarks on these documents follow:

(CN) This document describes the preparation and use of imidazopyridine derivatives as platelet agglutination inhibitors, anti-allergic, anti-inflammatory sedative, cardiac and cardiovascular vasodilators.

(BM) This document describes the preparation of pharmaceutical compositions of derivatives of benzimidazoles and azabenzimidazoles, which assertedly have cardiotonic, vasodilating, anti-hypertensive, anti-aggregation, and anti-ulcer activity. These compositions are assertedly useful as cardiotonics, vasodilators, anti-hypertensives, and anti-platelet aggregations agents. Further, these compounds assertedly have anti-ulcer activity and can be used in the treatment of gastroduodenal ulcers.

(BL) This document describes the preparation, manufacture, and use of heterocyclic, substituted azoles and azines as herbicides. Particular attention is drawn to their use for selective control of mono- and dicotyledonous weeds and are better tolerated than known compounds of similar structure.

(DM) This document refers to 2,3-dihydro-pyrido[1,2,3-de]-1,4-benzoxazine chloride compounds and a condensed hetercyclic ring structure which are assertedly useful as organic luminophores for marking agents.

(3) English translations of documents GP, FP, and FS were not available. English language abstracts were provided on the front page of the documents. Brief remarks on these documents follow:

(GP) This document describes the combination of one compound having progesterone-antagonistic properties with one compound having anti-estrogen properties. Each compound is used in a dose that would not inhibit ovulation by itself, but is effective when combined. The medicaments are discussed as being useful in female contraception.

(FP) WO 95/11013 describes the use of at least one compound with progesterone antagonistic action and at least one compound with anti-estrogen action, together with partial agonistic action, for drugs assertedly useful in hormone replacement therapy.

(FS) Vernin describes the preparation of 6-aryl- and 6-heteroaryl-2-ethylbenzothiazoles. The electrophilic character of the 2-ethyl-6-benzothiazolyl intermediate radicals is also discussed. A number of the 6-aryl and 6-heteroaryl-2-ethylbenzothiazoles were subsequently utilized to prepare corresponding quaternary salts and spriopyrans.

(4) Abstracts for documents AM and AN were obtained and were provided as documents, BS and BR, respectively. Applicants have also enclosed an English language translation of AN and have provided brief remarks on these documents as follow:

(AM) DE 4,330,234 relates to female fertility control comprising intermittent administration of competitive progesterone antagonist together with daily of continuous administration of gestagen. The gestagen may be levonorgestrel, gestodene, desogestrel or cyproterone acetate and the antagonist may be mifepristone or onapriston.

(AN) DE 4,344,463 relates to a contraceptive pack comprising a combination of individual dosage units of competitive progesterone antagonist in an amount which does not inhibit ovulation or promote abortion and individual dosage units of a gestagen for sequential oral administration. Administration can be oral, topical or local.

(5) An English translation of document HN was not available. However, document DK, US Patent No. 6,077,840, issued June 20, 2000, corresponds to document HN, International Patent Publication No. WO 98/27059 and is a parallel document to European Patent No. 947507 (document CL). A brief remark on this document follows:

(HN) This document describes a progesterone receptor binding inhibitor which is a tetrahydrobenzindolone derivative of the formula provided. The compound is described as useful as a carcinostatic agent.

(6) English language abstracts of FL and GQ were provided on the front page of the documents. Applicants also provide English language translations of these documents. Brief remarks on these documents follow:

(FL) This document describes the preparation and use of new bicyclo-imidazoles. The compounds of the invention are particularly directed toward the use in drugs to prevent clumping of both erythrocytes and thrombocytes.

(GQ) This document describes the preparation and use of heterocyclically-substituted 1-indole carboxamides, their pharmaceutically acceptable salts, and use as cyclo-oxygenase-2 inhibitors.

(7) English translations of documents CP, CQ, and DL were not available. However, document HK, US Patent No. 4,518,597, issued May 21, 1985, corresponds to document CP. Document EO, International Patent Publication No. WO-95/04048, published February 9, 1995, corresponds to document CQ. Document IA, US Patent No. 6,013,647, issued January 11, 2000, corresponds to document DL. Brief remarks on these documents follow:

(CP) This document describes novel benzoxazin-2-ones that have pharmacological properties in antithrombotic activity, which can be prepared using the methods for analogous compounds.

(CQ) This document describes new benzoxazinedione derivatives useful with antibiotic agents to improve antibacterial effects against relatively resistant bacterial strains.

(DL) This document describes the preparation and use of benzoxazinones and benzothiazinones, their pharmaceutically acceptable salts, and use as therapeutically active substances.

(8) English translations of documents DN, DP, and DQ were not available. However, document BK, U.S. Patent No. 5,447,928, issued September 5, 1995, corresponds to document DN. Document CH, U.S. Patent No. 5,659,046, issued August 19, 1997, corresponds to document DP. Document FQ, International Patent Application No. WO95/20389, published August 3, 1995, corresponds to document DQ. Brief remarks on these documents follow:

(DN) This document describes optically pure or mixtures of benzoxazine compounds useful as neuronal calcium antagonists. These compounds are assertedly useful in treating damage following ischaemic attack, cardiac or respiratory arrest, cerebral thrombosis or embolism, cerebral senility, dementias, Alzheimer's disease, Huntington's chorea, soliv-ponto-cerebellar atrophy, amyotrophic lateral sclerosis, cranial and spinal trauma, preventing neuronal damage following convulsions, and in treating cancers, neurological changes to the AIDS, and diabetic retinopathies.

(DP) This document describes methods of preparing 2-perfluoroalkyl-3 oxazolin-5-one, which are assertedly effective against insects, mites, and nematodes.

(DQ) This document describes benzoxainone compounds of the general formula:



where X=halogen

These compounds are assertedly useful for inhibiting the activity of HIV reverse transcriptase, prophylaxis, and treatment of HIV-infections and AIDS.

(9) An English translation of document DO could not be obtained. However, this document corresponds to document CE, U.S. Patent No. 5,552,412, issued September 3, 1996; document EB, U.S Patent No. 6,204,286, issued March 20, 2001 (which is a continuation of document CE); document EA, U.S. Patent No. 6,153,622, issued November 28, 2000 (which is a continuation-in-part of document EB); document FI, U.S. Patent No. 6,441,193, issued August 27, 2002 (which is a continuation of document EB); and document HA, U.S. Patent Publication No. US-2001-0025051A1, published September 27, 2001 (which is a continuation of document FI). Brief remarks on this document follow:

(DO) This document describes compounds of the following structure:



These compounds, their optic and geometric isomers and nontoxic pharmaceutically acceptable acid-additive salts assertedly have estrogen-antagonistic/agonistic activity.

(10) English translations of documents CO and EL-EN could not be obtained. However, English language abstracts of documents CO and EM-EN were provided as documents BT, BY, and CX. Further, documents BI, CF, and BG are the corresponding US patents for documents CO and EM-EN. The following comments for documents CO and EM-EN are also provided.

(CO) This document discusses compounds having the following structure:



These compounds are assertedly useful as having anti-arrhythmic activity, for anti-aggregation of blood-platelets, having beta-blocking properties, and for treating cardiac insufficiency, arrhythmia, migraines, and angina pectoris.

(EM) This document discusses compounds having the following structure:



wherein:

X is H, F, Cl, Br, C_{1-6} alkyl, C_{3-8} cycloalkyl, NO_2, CF_3, CN, SH, $S(O)_mR^3$, OR^4, COR^4, or $CONR^4R^5$; and
Y = H, F, Cl, Br, C_{1-6} alkyl, C_{3-8} cycloalkyl, NO_2, CF_3, CN, SH, $S(O)_qR^{17}$, OR^{18}, or $CONR^{18}R^{19}$.

These compounds are assertedly useful as analgesics, anti-inflammatories, and antiarthritic agents, and to inhibit IL-1 biosynthesis (osteoporosis, periodontal disease, and tissue scarring) and immune dysfunctions (allergies and psoriasis).

(EN) This document discusses compounds having the following structure:



wherein:

R = H, OH, or F;
R^1-R^4 = H, C_{1-4} alkyl, X, CF_3, phenyl, p-methylphenyl, or CF_3-phenyl; or
$R^1 + R^2$, $R^2 + R^3$, or $R^3 + R^4$ are joined to from a benzo-fused ring.

These compounds are assertedly useful in the treatment of disorders responsive to the opening of potassium channels such as ischemia, convulsions, asthma, and traumatic brain injuries.

(11) Applicants could not obtain an English translation or an English language abstract of document EL. However, from information provided on the Russian Patent Office web site Applicants were able to obtain an English language abstract of the priority application, i.e., Great Britain Patent Application No. 9326136. Further, document CG is the corresponding US patent to the priority application. The following comments for document EL are also provided.

(EL) This document discusses the following compounds:



R_4 = H, OH, C_{1-6} alkoxy, C_{2-6} alkanoyloxy, carboxy, nitro, or NHR; and
R_5 = H, C_{1-6} alkyl, or halogen.

These compounds are assertedly useful in inhibiting angiogenesis.

The month of publication for documents AR, AY, CU, CW, CY, DR, DV, DX, ES, ET, EU, EV, and EZ could not be determined. The years of publication for these documents are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the documents is not an issue (MPEP 609).

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By 
Cathy A Rodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US- 3,526,621	11-01-1970	Bernardi	
	AB	US- 3,635,941	01-18-1972	Weaver	
	AC	US- 3,635,964	01-18-1972	Skorcz	
	AD	US- 3,917,592	11-04-1975	Kobzina	
	AE	US- 4,093,730	06-06-1978	Butti	
	AF	US- 4,440,785	04-03-1984	Walsh	
	AG	US- 4,617,302	10-14-1986	Robertson	
	AH	US- 4,666,913	05-19-1987	Kuhla	
	AI	US- 4,670,566	06-02-1987	Walsh	
	AJ	US- 4,721,721	12-26-1988	Kuhla	
	AK	US- 4,792,561	12-20-1988	Walker	
	BA	US- 4,822,794	04-18-1989	Spada	
	BB	US- 4,831,027	05-16-1989	Narr	
	BC	US- 4,853,473	08-01-1989	Fischer	
	BD	US- 4,933,336	06-12-1990	Martin	
	BE	US- 5,007,952	04-16-1991	Kume	
	BF	US- 5,171,851	12-15-1992	Kim	
	BG	US- 5,182,282	01-26-1993	Clemence	
	BH	US- 5,246,989	09-21-1993	Iwamoto	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	AL	DE-3,633,861	04-07-1988	Narr		
	AM	DE-4,330,234	03-09-1995	Chwalisz		
	AN	DE-4,344,463	06-29-1995	Stockemann		✓
	AO	EP-022,317	01-14-1981	Watanabe		
	AP	EP-166,533	04-11-1990	Campbell		
	AQ	EP-208,510	01-14-1987	Kadin		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BI	US- 5,300,655	04-05-1994	Ehrgott	
	BJ	US- 5,414,088	05-09-1995	von der Saal	
	BK	US- 5,447,928	11-05-1995	Williams	
	CA	US- 5,453,516	09-26-1995	Fischer	
	CB	US- 5,475,020	12-12-1995	Johnson	
	CC	US- 5,519,021	05-21-1996	Young	
	CD	US- 5,521,166	05-28-1996	Grubb	
	CE	US- 5,552,412	09-03-1996	Cameron	
	CF	US- 5,565,483	10-15-1996	Hewawasam	
	CG	US- 5,576,330	11-19-1996	Buzzetti	
	CH	US- 5,659,046	08-19-1997	Kameswaran	
	CI	US- 5,681,817	10-28-1997	Hodgen	
	CJ	US- 5,688,808	11-18-1997	Jones	
	CK	US- 5,688,810	11-18-1997	Jones	
	DA	US- 5,693,646	12-02-1997	Jones	
	DB	US- 5,693,647	12-02-1997	Jones	
	DC	US- 5,696,127	12-02-1997	Jones	
	DD	US- 5,696,130	12-02-1997	Jones	
	DE	US- 5,696,133	12-02-1997	Jones	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	BL	EP-311,135	04-12-1989	Ganzer		
	BM	EP-385,850	09-05-1990	Bru-Magniez		
	BN	EP-454,330	10-30-1991	Hara		
	BO	EP-483,077	09-27-1991	Fraschini		
	BP	EP-510,235	10-28-1992	Kim		
	BQ	EP-535,529	09-24-1992	Takahashi		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	DF	US- 5,719,136	02-17-1998	Chwalisz	
	DG	US- 5,733,902	03-31-1998	Schneider	
	DH	US- 5,808,139	09-15-1998	Pathirana	
	DI	US- 5,874,430	02-23-1999	Christ	
	DJ	US- 6,013,652	01-11-2000	Maccoss	
	DK	US- 6,077,840	06-20-2000	Kurihara	
	EA	US- 6,153,622	11-28-2000	Cameron	
	EB	US- 6,204,286	03-20-2001	Cameron	
	EC	US- 6,306,851	10-23-2001	Santilli	
	ED	US- 6,319,912	11-20-2001	Grubb	
	EE	US- 6,329,416	12-11-2001	Grubb	
	EF	US- 6,339,098	01-15-2002	Collins	
	EG	US- 6,355,648	03-12-2002	Fensome	
	EH	US- 6,358,947	03-19-2002	Zhi	
	EI	US- 6,358,948	03-19-2002	Zhang	
	EJ	US- 6,369,056	04-09-2002	Zhang	
	EK	US- 6,380,178	04-30-2002	Grubb	
	FA	US- 6,380,235	04-30-2002	Zhang	
	FB	US- 6,391,907	05-21-2002	Fensome	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	CL	EP-947,507	10-06-1999	Kurihara		
	CM	EP-978,279	02-09-2000	Roth		
	CN	JP-63112584	05-17-1988	Tatsu		
	CO	RU-2067576-C1	10-10-1996	Clemence		
	CP	HU-194842B	03-28-1988	Narr		
	CQ	HU-P9600165-A	01-28-1997	Levi		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	FC	US-6,399,593	06-04-2002	Grubb	
	FD	US-6,407,101	06-18-2002	Collins	
	FE	US-6,417,214	07-09-2002	Ullrich	
	FF	US-6,423,699	07-23-2002	Grubb	
	FG	US-6,436,929	08-20-2002	Zhang	
	FH	US-6,441,019	08-27-2002	Santilli	
	FI	US-6,441,193	08-27-2002	Cameron	
	FJ	US-6,444,668	09-03-2002	Grubb	
	FK	US-6,462,032	10-08-2002	Grubb	
	GA	US-6,498,154	12-24-2002	Grubb	
	GB	US-6,503,939	01-07-2003	Grubb	
	GC	US-6,509,334	01-21-2003	Zhang	
	GD	US-6,521,657	02-18-2003	Fensome	
	GE	US-6,544,970	04-08-2003	Grubb	
	GF	US-6,566,358	05-20-2003	Zhang	
	GG	US-6,583,145	06-24-2003	Fensome	
	GH	US-6,562,857	05-13-2003	Collins	
	GI	US-6,608,068	08-19-2003	Fensome	
	GJ	US-6,693,103	02-17-2004	Zhang	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	DL	HU-P9800472-A	06-28-1999	Heinisch		
	DM	RU-2100359	12-27-1997	Kovelman		
	DN	RU-2130020	05-10-1999	Pol		
	DO	RU-2130454	05-20-1999	Kameron		
	DP	RU-213462	08-10-1999	Kameswaran		
	DQ	RU-2186775	08-10-2002	Jang		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	GK	US- 6,713,478	03-30-2004	Zhang	
	HA	US- 2001-0025051-A1	09-27-2001	Cameron	
	HB	US- 2002-0169198-A1	11-14-2002	Fensome	
	HC	US- 2003-0158182-A1	08-21-2003	Fensome	
	HD	US- 2003-0220388-A1	11-27-2003	Fensome	
	HE	US- 2003-0225109-A1	12-04-2003	Fensome	
	HF	US- 2002-0115853-A1	08-22-2002	Zhang	
	HG	US- 2002-0151531-A1	10-17-2002	Grubb	
	HH	US- 2003-0008909-A1	01-09-2003	Ullrich	
	HI	US- 2003-0045511-A1	03-06-2003	Grubb	
	HJ	US- 2003-0092711-A1	05-15-2003	Zhang	
	HK	US- 4,518,597	05-21-1985	Narr	
	IA	US- 6,013,647	01-11-2000	Heinisch	
	IB	US- 2002-0111355-A1	08-15-2002	Zhang	
	IC	US- 2004-0006122-A1	01-08-2004	Fensome	
	ID	US- 2004-0014798-A1	01-22-2004	Fensome	
	IE	US- 2004-0002535-A1	01-01-2004	Fensome	
	IF	US- 2004-0006060-A1	01-08-2004	Fensome	
	IG	US- 2003-0083322-A1	05-01-2003	Kraemer	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	EL	RU-95121739-A	02-10-1998	Buzzetti		
	EM	RU-2073671-C1	02-20-1997	Ehrgott		
	EN	RU-2165925	04-27-2001	Hewawasam		
	EO	WO-95/04048	02-09-1995	Levi		
	EP	WO-86/03749	07-03-1986	Kuhla		
	EQ	WO-91/04974	04-18-1991	von der Saal		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	FL	WO-91/06545	05-16-1991	von der Saal		✓
	FM	WO-93/12085	06-24-1993	Boar		
	FN	WO-94/14434	07-07-1994	Elliott		
	FO	WO-94/29272	12-22-1994	Boar		
	FP	WO-95/11013	04-27-1995	Chwalisz		
	FQ	WO-95/20389	08-03-1995	Young		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	GL	WO-95/20972	08-10-1995	Hodgen		
	GM	WO-95/33746	12-14-1995	Kamireddy		
	GN	WO-96/15794	05-30-1996	Spicer		
	GO	WO-96/19458	06-27-1996	Jones		
	GP	WO-96/19997	07-04-1996	Chwalisz		
	GQ	WO-97/13767	04-17-1997	Binder		✓

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	HL	WO-97/49407	12-31-1997	Coelingh Bennin		
	HM	WO-98/14436	04-09-1998	Christ		
	HN	WO-98/27059	06-25-1998	Kurihara		
	HO	WO-98/55116	12-10-1998	Goulet		
	HP	WO-99/10325	03-04-1999	McNutt		
	HQ	WO-99/11264	03-11-1999	Widdowson		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	IL	WO-99/15500	04-01-1999	Davis		
	IM	WO-99/44608	09-10-1999	Ramachandran		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/767,813
				Filing Date	January 29, 2004
				First Named Inventor	Zhang et al.
				Group Art Unit	unassigned
(Use as many sheets as necessary)				Examiner Name	unassigned
Sheet	10	of	15	Attorney Docket Number	AHPWA1DUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	AR	ANDREANI et al., "Potential antitumor agents XVII(1). Cytotoxic agents from indole derivatives and their intermediates", *Acta. Pharm. Nord.* **1990** 2(6):407-414	
	AS	ARNDT et al., "New Heterocycle substituted Benzo-Fused Azine and Azole Derivatives - Useful as Selective Herbicides for Pre or Post-Emergence Application", **October 10, 1988** Derwent WPI Abstract EP 311135	
	AT	BARENGOLTS et al., "Progesterone antagonist RU486 has bone-sparing effects in ovariectomized rats", *Bone* **July 1995** 17(1):21-25	
	AU	BARTSCH, et al., "3-Amino ethyl benzoxazine derivs - useful for the prevention and treatment of cerebral disorders such as senile dementia", **November 10, 1995** Derwent WPI abstract of Russian Patent No. RU 94007350	
	AV	BRUMAGNIEZ et al., "Benzimidazole and Azabenzimidazole(s) - Having Cardiotonic, Vasodilating, Anti-Hypertensive, Anti-Aggregation, and Anti-Ulcer Activity", **February 27, 1990** Derwent WPI Abstract EP 385850	
	AW	BUZZETTI et al., "3-(Bicyclylmethylene)oxindole antiangiogenic agents", **November 19, 1996** Abstract of US Patent No. 5,576,330	
	AX	CANONNE et al., "Spirocyclization of 1-(o-Aminophenyl)cycloalkanols and 1-(2'-Amino-3'-pyridinyl)cycloalkanols", *J. Heterocyclic Chem.* **January-February 1989** 26:113	
	AY	CHEN et al., "Synthesis and SAR of a novel series of spirobenzothlzaepine derivatives with antiprogestin activity", POI-37, 16th Int. Cong. Het. Chem., Montana **1997**	
	AZ	CHIARINO et al., "2,1-Benzisothiazoline 2,2-Dioxide and derivatives", *J. Heterocycl. Chem.* **November-December 1986** 23(6):1645-1649	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/767,813
				Filing Date	January 29, 2004
				First Named Inventor	Zhang et al.
				Group Art Unit	unassigned
(Use as many sheets as necessary)				Examiner Name	unassigned
Sheet	11	of	15	Attorney Docket Number	AHPWA1DUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	BR	CHWALISZ et al. "Contraceptive Pack for Implantation Inhibition - Contains Competitive Progesterone Antagonist and Gestagen for Sequential Oral Administration.", **June 29, 1995** Derwent WPI Abstract DE 4,344,463	
	BS	CHWALISZ et al. "Female Contraceptive Method Comprises Gestation Treatment with Intermittent Progesterone Antagonist Administration.", **March 9, 1995** Derwent WPI Abstract DE 4,330,234	
	BT	CLEMENCE et al., "New 4-(amino-alkoxy-phenyl-methyl)1H-indole derivatives", **October 10, 1996** Abstract of Russian Patent No. 2067576	
	BU	COMBS et al., "Heteroatom analogues of bemoradan: Chemistry and cardiotonic activity og 1,4-Benzothiazinylpyridazinones", *J. Med. Chem.* **January 1992** 35:172-176	
	BV	COMBS et al., "Nonsteroidal progesterone receptor ligands. 2. High-affinity ligands with selectivity for bone cell progesterone receptors", *J. Med. Chem.* **December 8, 1995** 38:4880	
	BW	Derwent WPI Abstract, "New Imidazo-Pyridine Derivatives - Useful as Platelet Agglutination Inhibitor, Antiallergic, Antiinflammatory Sedative, Cardiac, and Cardiovascular Vasodilators", **May 17, 1988** JP 63112584	
	BX	EDWARDS et al., "5-Aryl-1,2-Dihydro-5H-Chromeno[3,4-f]Quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: The effect of D-ring substituents", *J. Med. Chem.* **January 29, 1998** 41:303-310	
	BY	EHRGOTT et al., "New 1,3-disubstituted-2-oxo-indole derivatives", **February 20, 1997** Abstract of Russian Patent No. 2073671	
	BZ	EVANS, "The steroid and thyroid hormone receptor superfamily", *Science* **May 13, 1988** 240(4854):889-895	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/767,813
				Filing Date	January 29, 2004
				First Named Inventor	Zhang et al.
				Group Art Unit	unassigned
(Use as many sheets as necessary)				Examiner Name	unassigned
Sheet	12	of	15	Attorney Docket Number	AHPWA1DUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	CR	FENSOME et al., "New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles", *Bio. & Med.Chem. Lett.* **December 2, 2002** 12(23):3487-3490	
	CS	FENSOME et al., "Novel 5-aryl-1,3-dihydro-indole-2-thiones: Potent, orally active progesterone receptor agonists", *Bio. & Med. Chem. Lett.* **April 7, 2003** 13(7):1317-1320	
	CT	FOREST et al., "A novel class of cardiotonic agents: Synthesis and biological evaluation of 5-substituted 3,6-dihydrothiadiazin-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium sensitizing properties", *J. Med. Chem.* **January 1992** 35:163-172	
	CU	GROMACHEVSKAYA et al., "Studies of 4H-3,1-Benzoxazines", *Chem. Hetercycl. Compds.* **1997** 33(10):1209-1214	
	CV	HAMANN et al., "Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists", *Ann. N.Y. Acad. Sci.* **June 12, 1995** 761:383-387	
	CW	HARTMANN et al., "Effects of brofoxine, a new anxiolytic on experimentally induced conflict in rats", *Proc. West. Pharmacol. Soc.* **1978** 21:51-55	
	CX	HEWAWASAM et al., "New 3-Phenyl oxindole derivatives", **April 27, 2001** Abstract of Russian Patent No. 2165925	
	CY	HORWITZ et al., "Progestin, progesterone receptors, and breast cancer", *Hormone Cancer*, (Vedeckis ed.) Birkhaeuser: Boston,Massachusetts **1996** pp. 283-306 (abstract)	
	CZ	KEKKONEN et al., "Sequential regiment of the antiprogesterone RU486 and synthetic progestin for contraception", *Fertility and Sterility* **October 1993** 60(4):610-615	
	DR	KENDE et al., "Regioselective C-3 alkylation of oxindole dianion", *Synth. Commun.* **1982** 12(1):1	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/767,813
				Filing Date	January 29, 2004
				First Named Inventor	Zhang et al.
				Group Art Unit	unassigned
(Use as many sheets as necessary)				Examiner Name	unassigned
Sheet	13	of	15	Attorney Docket Number	AHPWA1DUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	DS	KETTEL et al., "Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis", *Fertility and Sterility* **September 1991** 56(3):402-407	
	DT	KOLASA et al., "Preliminary Pharmacological Studies of the Central Action of Phenyl and Piperidinomethyl Derivatives of 2-Benzoxazolone", *Chemical Abstracts* **July 4, 1983** Vol. 99, No. 1, Abst. No. 157a	
	DU	KOVEMAN, et al., "Condensed heterocyclic ring structure compounds used organic luminophores, etc. - comprises 2, 3- dihydro-pyrido-1, 2, 3-de-1, 4-benzoxazine chloride and its derivatives ", **December 27, 1997** Derwent WPI abstract of Russian Patent No. RU 2100359	
	DV	KUMAR et al., "Synthesis of 7-Azaindole and 7-Azaxindole derivatives through a palladium-catalyzed cross-coupling reaction", *J. Org. Chem.* **1992** 57(25):6995-6998	
	DW	KURIHARI et al., "Synthesis of (±)-PF1092A, B, and C; New nonsteroidal progesterone receptor ligands", *J. Antibiotics* **April 1997** 50(4):360	
	DX	MAMAEV et al., "Synthesis of 4H-Thieno [3,2-B] Pyrrol-5(6H)-One" *Bulletin of the Academy of Sciences on the USSR.* Division of Chemical Science, US, Consultants Bureau. **1966** New York. Vol. 9, p. 1549-1553	
	DY	MEANWELL et al., "Regiospecific Functionalization of 1,3-dihydro-2H-Benzimidazol-2-One and Structurally Related Cyclic Urea Derivatives", *J. Organic Chem.* **March 24, 1995** 60(6):1565-1582	
	DZ	MICHNA et al., "Differentiation therapy with progesterone antagonists", *Ann. N.Y. Acad. Sci.* **June 12, 1995** 761:224-247	
	ER	MURPHY et al., "Regression of uterine leiomyomata in response to the antiprogesterone RU486", *J. Clin. Endo. Metab.* **February 1993** 76(2):513-517	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 15

Complete if Known	
Application Number	10/767,813
Filing Date	January 29, 2004
First Named Inventor	Zhang et al.
Group Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	AHPWA1DUSA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	ES	NARR et al., "Preparation, testing, and formulation of Imidazobenzoxazinones as cardiotonics", *Chemical Abstracts* **1988** 109:22973	
	ET	PERLMAN et al., "20-Oxopregnacalciferols:Vitamin D Compounds that bind the progesterone receptor", *Tet. Letters* **1994** 35(15):2295	
	EU	PFLEGEL et al., "Polarografie con 7-Chlor-5-phenly-2-thioxo-1H-2,3-dihydro-1,3,4-benzotriazepinen", *Pharmazie* **1982** 37(10):714-717	
	EV	SAKATA et al., "Silver halide photographic materials useful for platemaking", *Chemical Abstracts* **1993** 123:301431	
	EW	SINGH et al., "An Efficient and Novel Synthesis of Fused Thiazol-2(3H)-ones" *Heterocycles* **January 1993** 36(1):133-134	
	EX	SINGH et al., "Novel cAMP PDE III inhibitor Imidazo[4,5-b]pyridin-2(3H)-ones and Thiazolo[4,5-b]pyridin-2(3H)-ones and their analogs", *J. Med. Chem.* **January 21, 1994** 37:248	
	EY	TUCKER et al., "Synthesis of a series of 4-(Arylethylnyl)-6-Chloro-4-Cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nuceloside HIV-1 reverse transcriptase inhibitors", *J. Med. Chem.* **July 22, 1994** 37:2347-2444	
	EZ	TURCK et al., "On the metabolism of 3-substituted and 3,6-disubstituted pyridazines", *Tetrahedron* **1993** 49(3):599-606	
	FR	ULMANN et al., "Clinical uses of mifepristone (MFP)", *Ann. N.Y. Acad. Sci.* **June 12, 1995** 261:248	
	FS	VERNIN et al., "Etude Dans la Serie des Radicaux Heterocycliques. Partie XV. Decomposition aprotique de 1' amino-6-ethyl-2-benzothiazole dans des substrats aromatiques et heteroaromatiques: preparation des mesityl-6- et furyl-6-ethyl-2-benzothiazoles, des sels quaternaires et des spiropyrannes correspondants", *Helvetica Chimica Acta* **January 24, 1979** 62(1/3):21-30	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/767,813
				Filing Date	January 29, 2004
				First Named Inventor	Zhang et al.
				Group Art Unit	unassigned
(Use as many sheets as necessary)				Examiner Name	unassigned
Sheet	15	of	15	Attorney Docket Number	AHPWA1DUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	FT	ZHI et al., "5-Aryl-1,2-Dihydrochromeno[3,4-f]quinolines: A novel class of nonsteroidal human progesterone receptor agonists", *J. Med. Chem.* **January 29, 1998** 41(3):291-302	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.